Repligen | RGEN - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Agilent USD 6.91B 167M 2025-12
Align Technology USD 3.96B 44.68M 2025-09
Bio Techne USD 2.01B 45.18M 2025-12
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Bruker USD 2.49B 625.6M 2025-09
Charles River Laboratories USD 3.16B 240.82M 2025-12
Danaher USD 52.53B 1.46B 2025-12
Dentsply International USD 1.34B 139M 2025-12
General Electric Aerospace USD 18.9B 86M 2025-12
Henry Schein USD 3.24B 116M 2025-12
Illumina USD 2.72B 342M 2025-12
IQVIA Holdings USD 6.5B 343M 2025-12
Mettler Toledo International USD -23.64M 225.56M 2025-12
Myriad Genetics USD 368M 4.8M 2025-12
OraSure Technologies USD 340.83M 21.15M 2025-12
Pacific Biosciences Of California USD 5.35M 30.74M 2025-12
Pfizer USD 92.8B 4.11B 2025-09
Repligen USD 2.11B 1.66B 2025-12
Revvity USD 7.38B 180.27M 2025-09
Standard Biotools USD 424.29M 24.63M 2025-12
Thermo Fisher Scientific USD 53.54B 2.38B 2025-12
Waters USD 2.56B 230.55M 2025-12
West Pharmaceutical Services USD 3.18B 124.5M 2025-12